Pharmaceutical giant AstraZeneca reports this week its revenue declined by 3 percent in the third quarter of the year.
The British drugmaker, which has its US headquarters just outside Wilmington, says the decline in revenue was driven by a slump in sales for its cholesterol drug Crestor.
The three month period between July and September was the first full quarter Crestor faced competition from generics.
In a statement, AstraZeneca said the decline in sales was in line with its expectations.
It added that its development of new medicines for lung cancer, ovarian cancer and uncontrollable asthma are moving at a pace that exceeds its expectations.
The company employs nearly 22 hundred people in Delaware at its headquarters in Fairfax and a Newark packaging facility.
It put its Fairfax campus up for sale in August, but says it is committed to staying in Delaware - either saying in Fairfax or moving to a nearby location.